188 related articles for article (PubMed ID: 30911893)
1. Genome-Wide Response to Drugs and Stress in the Pathogenic Yeast Candida glabrata.
Pais P; Galocha M; Teixeira MC
Prog Mol Subcell Biol; 2019; 58():155-193. PubMed ID: 30911893
[TBL] [Abstract][Full Text] [Related]
2. Membrane Proteome-Wide Response to the Antifungal Drug Clotrimazole in Candida glabrata: Role of the Transcription Factor CgPdr1 and the Drug:H+ Antiporters CgTpo1_1 and CgTpo1_2.
Pais P; Costa C; Pires C; Shimizu K; Chibana H; Teixeira MC
Mol Cell Proteomics; 2016 Jan; 15(1):57-72. PubMed ID: 26512119
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
4. Expression of Efflux Pumps and Fatty Acid Activator One Genes in Azole Resistant Candida Glabrata Isolated From Immunocompromised Patients.
Farahyar S; Zaini F; Kordbacheh P; Rezaie S; Falahati M; Safara M; Raoofian R; Hatami K; Mohebbi M; Heidari M
Acta Med Iran; 2016 Jul; 54(7):458-64. PubMed ID: 27424018
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
8. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
9. Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study.
Biswas C; Chen SC; Halliday C; Kennedy K; Playford EG; Marriott DJ; Slavin MA; Sorrell TC; Sintchenko V
Clin Microbiol Infect; 2017 Sep; 23(9):676.e7-676.e10. PubMed ID: 28344162
[TBL] [Abstract][Full Text] [Related]
10. Transient Mitochondria Dysfunction Confers Fungal Cross-Resistance against Phagocytic Killing and Fluconazole.
Siscar-Lewin S; Gabaldón T; Aldejohann AM; Kurzai O; Hube B; Brunke S
mBio; 2021 Jun; 12(3):e0112821. PubMed ID: 34061590
[TBL] [Abstract][Full Text] [Related]
11. A Review on Molecular Mechanisms of Antifungal Resistance in
Lotfali E; Fattahi A; Sayyahfar S; Ghasemi R; Rabiei MM; Fathi M; Vakili K; Deravi N; Soheili A; Toreyhi H; Shirvani F
Microb Drug Resist; 2021 Oct; 27(10):1371-1388. PubMed ID: 33956513
[No Abstract] [Full Text] [Related]
12. Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction.
Nishikawa JL; Boeszoermenyi A; Vale-Silva LA; Torelli R; Posteraro B; Sohn YJ; Ji F; Gelev V; Sanglard D; Sanguinetti M; Sadreyev RI; Mukherjee G; Bhyravabhotla J; Buhrlage SJ; Gray NS; Wagner G; Näär AM; Arthanari H
Nature; 2016 Feb; 530(7591):485-9. PubMed ID: 26886795
[TBL] [Abstract][Full Text] [Related]
13. The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata.
Borah S; Shivarathri R; Kaur R
J Biol Chem; 2011 Sep; 286(39):34311-24. PubMed ID: 21832071
[TBL] [Abstract][Full Text] [Related]
14. Candida glabrata--unique features and challenges in the clinical management of invasive infections.
Glöckner A; Cornely OA
Mycoses; 2015 Aug; 58(8):445-50. PubMed ID: 26207423
[TBL] [Abstract][Full Text] [Related]
15. Tipping the balance both ways: drug resistance and virulence in Candida glabrata.
Vale-Silva LA; Sanglard D
FEMS Yeast Res; 2015 Jun; 15(4):fov025. PubMed ID: 25979690
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
17. Amino acid substitutions in Erg11p of azole-resistant Candida glabrata: Possible effective substitutions and homology modelling.
Nabili M; Abdollahi Gohar A; Badali H; Mohammadi R; Moazeni M
J Glob Antimicrob Resist; 2016 Jun; 5():42-6. PubMed ID: 27436465
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes.
Posteraro B; Sanguinetti M; Fiori B; La Sorda M; Spanu T; Sanglard D; Fadda G
J Antimicrob Chemother; 2006 Aug; 58(2):458-61. PubMed ID: 16757500
[TBL] [Abstract][Full Text] [Related]
19. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil.
Canela HMS; Cardoso B; Vitali LH; Coelho HC; Martinez R; Ferreira MEDS
Mycoses; 2018 Jan; 61(1):11-21. PubMed ID: 28940753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
